Market Closed -
Nasdaq
04:30:00 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
10.67
USD
|
+0.12%
|
|
-3.33%
|
+40.06%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,206
|
81.76
|
49.56
|
69.42
|
-
|
-
|
Enterprise Value (EV)
1 |
1,752
|
81.76
|
49.56
|
69.42
|
69.42
|
69.42
|
P/E ratio
|
-11.6
x
|
-0.37
x
|
-0.32
x
|
-0.94
x
|
-1.09
x
|
-19.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-17,422,944
x
|
-430,239
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-18,070,929
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.98
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
6,446
|
6,489
|
6,504
|
6,504
|
-
|
-
|
Reference price
2 |
342.2
|
12.60
|
7.620
|
10.67
|
10.67
|
10.67
|
Announcement Date
|
3/7/22
|
3/31/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.138
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-126.6
|
-190
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-155.6
|
-226.5
|
-159.2
|
-
|
-53.15
|
-11.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-156.8
|
-225.2
|
-156.1
|
-
|
-52.08
|
-11.7
|
Net income
|
-37.74
|
-156.8
|
-223.2
|
-156.1
|
-
|
-52.08
|
-11.7
|
Net margin
|
-27,346.38%
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-56.60
|
-29.60
|
-34.40
|
-24.00
|
-11.39
|
-9.783
|
-0.5500
|
Free Cash Flow
|
-
|
-122.1
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/21
|
3/7/22
|
3/31/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-53.75
|
-54.29
|
-58.72
|
-56.65
|
-56.8
|
-33.89
|
-16.57
|
-20.43
|
-13.02
|
-23.96
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-54.29
|
-54.6
|
-59.6
|
-56.6
|
-54.45
|
-57.07
|
-18.66
|
-67.43
|
-12.92
|
-24.3
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-55.35
|
-54.6
|
-58.99
|
-56.22
|
-53.84
|
-57.07
|
-18.66
|
-67.43
|
-12.92
|
-24.3
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-9.000
|
-8.400
|
-9.200
|
-8.600
|
-8.200
|
-8.800
|
-2.800
|
-10.40
|
-1.990
|
-3.740
|
-2.920
|
-2.630
|
-2.350
|
-2.960
|
-3.620
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/7/22
|
5/16/22
|
8/12/22
|
11/14/22
|
3/31/23
|
5/11/23
|
8/14/23
|
11/13/23
|
3/21/24
|
5/10/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
454
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-122
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-60.8%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
86.10
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
57.8
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/21
|
3/7/22
|
3/31/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
10.67
USD Average target price
20.33
USD Spread / Average Target +90.51% Consensus |
1st Jan change
|
Capi.
|
---|
| +40.06% | 69.42M | | +55.55% | 59.28B | | +43.79% | 40.94B | | -4.71% | 40.17B | | -5.56% | 28.69B | | +13.76% | 26.63B | | -22.00% | 18.89B | | +31.50% | 12.46B | | +2.16% | 12.42B | | +25.70% | 12.26B |
Other Biotechnology & Medical Research
|